Addendum

Entrectinib (NSCLC) - Addendum to Commission A20-75

Report documents

Indication:

Adults with ROS1-positive, advanced NSCLC not previously treated with ROS1 inhibitors

Result of dossier assessment:

Added benefit still not proven

Federal Joint Committee (G-BA)

2021.02.18 A G-BA decision was published.

Project no.: A21-06
Commission: Commission awarded on 13.01.2021 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.